Abstract Adenocarcinoma of the pancreas is a significant cause of cancer mortality, and up to 10 % of cases appear to be familial. Heritable genomic copy number variants (CNVs) can modulate gene expression and predispose to disease. Here, we identify candidate predisposition genes for familial pancreatic cancer (FPC) by analyzing germline losses or gains present in one or more high-risk patients and absent in a large control group. A total of 120 FPC cases and 1,194 controls were genotyped on the Affymetrix 500K array, and 36 cases and 2,357 controls were genotyped on the Affymetrix 6.0 array. Detection of CNVs was performed by multiple computational algorithms and partially validated by quantitative PCR. We found no significant difference in the germline CNV profiles of cases and controls. A total of 93 non-redundant FPC-specific CNVs (53 losses and 40 gains) were identified in 50 cases, each CNV present in a single individual. FPC-specific CNVs overlapped the coding region of 88 RefSeq genes. Several of these genes have been reported to be differentially expressed and/or affected by copy number alterations in pancreatic adenocarcinoma. Further investigation in high-risk subjects may elucidate the role of one or more of these genes in genetic predisposition to pancreatic cancer.
Introduction
Adenocarcinoma of the pancreas is the fourth leading cause of cancer death in North America. This disease is usually diagnosed at an advanced inoperable stage and pancreas cancer is generally resistant to chemotherapy and radiotherapy, thus overall 5-year survival rates are poor (\5 %). Even curative-intent surgery fails in about 80 % of resected cases as locoregional and systemic recurrences are common (Vincent et al. 2011) . Improving outcome for pancreatic cancer patients depends on a better understanding of its etiology to foster early detection and intervention strategies. Although most pancreatic cancers are not obviously heritable, a significant fraction (5-10 %) of cases appears to be familial. About 20 % of hereditary pancreatic cancers are part of known cancer syndromes [Peutz-Jeghers Syndrome (PJS), STK11; familial atypical multiple mole melanoma (FAMMM), p16/CDKN2A; hereditary breast and ovarian cancer (HBOC), BRCA2/ BRCA1/PALB2; and hereditary pancreatitis (HP), PRSS1], but most cases of familial pancreatic cancer (FPC) have an unknown genetic etiology . Segregation analysis of families with multiple affected members suggests that FPC is caused by heritable alterations in at least one rare ''major gene'', likely in an autosomal dominant manner (Klein et al. 2002) . Moreover, multiple casecontrol and cohort studies have demonstrated that members of FPC families, particularly those with an affected firstdegree relative, have a significantly elevated lifetime risk of developing the disease (up to 32-to 56-fold) (Tersmette et al. 2001; Klein et al. 2004; Brune et al. 2010) . However, to date traditional methods of linkage analysis for identifying predisposition genes have met with challenges in studying FPC, due in part to probable genetic heterogeneity as well as difficulty in collecting DNA specimens on multiple affected members in a family due to the rapid mortality of the disease.
Recently, it has become clear that submicroscopic copy number variants (CNVs) are prevalent throughout all genomes, accounting for at least 1.2 % of nucleotide variation between any two individuals (Pang et al. 2010) . CNVs have been linked to rare genomic disorders (Gu and Lupski 2008) as well as common neurodevelopmental (Morrow 2010) , psychiatric (Alaerts and Del-Favero 2009) , autoimmune (Schaschl et al. 2009 ) and metabolic (Lanktree and Hegele 2008) diseases. Some studies have suggested an association between common CNVs and sporadic cancers [e.g. pancreatic cancer (6q13), Huang et al. 2012 ; neuroblastoma (1q21.1), Diskin et al. 2009; prostate cancer (2p24.3; 20p13 ; GSTT1), Liu et al. 2009; Jin et al. 2011; Nørskov et al. 2011; nasopharyngeal carcinoma (6p21. 3), Tse et al. 2011 ; and endometrial cancer (GSTT1), Karageorgi et al. 2011] . The recent paper by Huang et al. (2012) is the first to describe an association of a germline CNV with pancreatic cancer risk: a common 10,379 bp deletion at 6q13 was found to be higher in frequency in sporadic pancreatic cancer patients compared to controls, with an odds ratio of 1.31 for one-copy carriers compared to two-copy carriers. Interestingly, functional analysis of this non-genic deletion suggested that it may be involved in long-range regulation of CDKN2B, an established tumor-suppressor gene.
In addition, it is well known that rare germline CNVs contribute to the genetic basis of familial cancer. Indeed, large germline genomic rearrangements cause 15 % of familial adenomatous polyposis (APC gene) (Michils et al. 2005) , 2 % of breast and ovarian cancer (BRCA1 gene) (Engert et al. 2008) , and 5 % of Lynch Syndrome (MSH2 and MLH1 genes) (Taylor et al. 2003) cases. In 1-3 % of Lynch syndrome patients, the causative mutation is a large heritable deletion at the 3 0 end of the TACSTD1 gene, which causes transcriptional read-through and epigenetic silencing of the adjacent MSH2 gene (Kuiper et al. 2011) . Furthermore, a report by Shlien et al. (2008) identified an elevated frequency of germline CNVs in individuals with Li Fraumeni syndrome (TP53 mutation), and suggested that the increased predisposition to cancer in this syndrome may be proportional to the frequency of germline CNVs, many of which overlap known cancer genes.
Since germline CNVs implicated in familial cancers to date are rare with relatively high penetrance, we hypothesized that genes overlapped by rare germline genomic losses or gains identified exclusively in pancreatic cancer patients from high-risk families are candidate FPC genes. Here, we present an analysis of germline CNVs detected in 120 high-risk pancreatic cancer patients and compare them to CNVs in a large cohort of unaffected controls. 
Materials and methods

This
Cases and controls
Genomic DNA was extracted from peripheral blood or EBV-transformed cell lines of 133 pancreatic cancer patients from 131 high-risk families recruited by PAC-GENE (Pancreatic Cancer Genetic Epidemiology Consortium; PI, G Petersen, Mayo) (Petersen et al. 2006 ), a sixcentre consortium that recruits kindreds containing two or more blood relatives affected with pancreatic cancer for genetic studies. Inclusion criteria in the current study included subjects with two or more affected relatives (''3 ? FPC''; N = 79); subjects with only one affected relative diagnosed at age 49 years or younger (''2 FPC''; N = 22); and subjects without affected relatives who were diagnosed at age 49 years or younger (''single young''; N = 32) (some of the families were reassigned based on updated information after analysis; see ''Results''). We included young cases with no family history of pancreatic cancer because they may have de novo mutations in the gene(s) of interest, although we acknowledge that the definition of FPC involves more than one affected member in the family. Subjects were excluded if they carried known mutations or were in families with syndromes which predispose to pancreatic cancer (BRCA2, BRCA1, p16/FAM-MM, STK11/PJS, PRSS1/HP, Lynch syndrome). The majority of DNA samples were extracted from blood (N = 97) and the remaining samples were from EBVtransformed lymphoblast cell lines (Online Resource 1). Of the original 128 FPC cases genotyped on the Affymetrix 500K array (see ''SNP genotyping and CNV discovery''), eight were subsequently excluded (two subjects had excessively noisy data based on CNV count [40 per analysis run; one subject was discovered to have had chronic lymphocytic leukemia at the time of blood sample donation, making it difficult to distinguish germline from somatic CNVs detected in the sample; and five subjects no longer met inclusion criteria in light of new information that became available after the start of the study), leaving 120 cases in the final analysis with both NspI and StyI chips represented for each sample. Some of the subjects were reassigned to different inclusion criteria after updated information became available, resulting in 68 ''3 ? FPC'' subjects, 28 ''2 FPC'' subjects, and 24 ''single young'' subjects contributing to the final set of case CNVs detected on Affymetrix 500K array.
Control samples of matched ancestry ([95 % of cases and controls reported Caucasian ancestry) were obtained from two sources: 45 samples were healthy controls recruited by the Familial Gastrointestinal Cancer Registry (FGICR) (Madlensky et al. 1995) at Mount Sinai Hospital, Toronto, and 1,153 samples were recruited by the Ontario Familial Colon Cancer Registry (OFCCR) (Cotterchio et al. 2005) . Almost all control DNA samples were extracted from blood (only 12 OFCCR controls were from lymphoblasts) (Online Resource 2). Two controls were discovered to have a history of sporadic pancreatic cancer (no affected relatives), and two other controls each reported having two relatives with pancreatic cancer, suggesting potential FPC kindreds. After excluding those four samples, 1,194 controls remained in the final analysis.
In addition, we had access to CNV data for 1,234 controls recruited through the Ottawa Heart Institute (OHI) (Stewart et al. 2009 ) and 1,123 controls of German descent recruited by the POPGEN project (Krawczak et al. 2006) . Most of the OHI and POPGEN DNA samples were extracted from blood, and the platform for CNV detection was the Affymetrix 6.0 array.
SNP genotyping and CNV discovery
One hundred and twenty-eight cases and all 1,198 controls were genotyped at approximately 500,000 genome-wide SNPs on the Affymetrix GeneChip Human Mapping 500K Array (NspI and StyI chips) according to standard protocol as provided by the manufacturer, and genotype calls were made by Affymetrix Genotyping Console (GTC 2.1) software. Copy number losses and gains were estimated using three validated Hidden Markov Model (HMM)-based algorithms (dCHIP, Li and Hung Wong 2001; CNAG, Nannya et al. 2005; and Partek Genomics SuiteÓ) . For each sample, all CNV calls from multiple algorithms and/ or chips that overlapped by at least 20 % were merged, and CNVs supported by two or more algorithms or chips were considered to be the set of ''high-confidence'' calls. CNV loci were identified as regions where CNVs from multiple samples overlapped (case and control loci were identified separately) (Online Resource 3 and 4). For 236 controls, only one chip was included in the analysis (137 NspI only; 99 StyI only) due to inadequate hybridization of the second chip.
A subset of the original FPC cohort (33 samples) and five new cases were genotyped on the Affymetrix 6.0 array according to standard protocol as provided by the manufacturer to validate CNVs detected on the Affymetrix 500K array and to detect new CNVs. Arrays meeting Affymetrix quality control guidelines of Contrast QC [0.4 were used for further analysis. The Affymetrix Power Tools platform was used to extract normalized intensities for each array and inter-array intensity correlation was calculated; arrays with average correlation [0.9 were considered suitable for joint analysis. CNV calling was performed using the Birdsuite (Canary ? Birdseye) (Korn et al. 2008 ) and iPattern (Pinto et al. 2011 ) algorithms, using a reference set that included the 38 FPC cases in addition to 100 other closely correlated Affymetrix 6.0 arrays genotyped at approximately the same time at The Centre for Applied Genomics (TCAG) in Toronto, Canada. (Samples were also analyzed on GTC 4.1, but these data were only used to support calls made on Birdsuite or iPattern.) Detection by either Birdsuite or iPattern was sufficient for the purpose of validating 500K array CNVs. Only ''high-confidence'' calls (i.e. called by at least two of Birdsuite, iPattern, and/or GTC 4.1 software) were included as novel FPC-specific CNVs.
To verify population ancestry of cases and controls, the program STRUCTURE (Pritchard et al. 2000) was used to estimate ancestry based on clustering of genotypes at 1,089 unlinked autosomal SNPs and assuming three ancestral populations. Genotypes for 270 HapMap samples from CEU, YRI, and CHB/JPT populations were used as reference of known ancestry during clustering. Ancestries were assigned using a co-efficient of ancestry threshold [0.9.
Quantitative PCR validation of CNVs
Quantitative PCR (qPCR) validation of some CNVs was performed using Invitrogen Platinum SYBR Green qPCR Supermix-UDG, with primers designed within the CNV of interest, and MSH2 as a reference gene. Reactions were performed in replicates of 4-8x. After using a standard curve to confirm that primer efficiency was appropriate (90-110 %), data were analyzed using the ddC t method (Schmittgen and Livak 2008) .
FPC-specific CNVs
We defined ''FPC-specific CNVs'' as losses or gains detected in FPC cases on the 500K or Affymetrix 6.0 array, and which did not overlap (by 20 % or more) with losses or gains in FCIGR, OFCCR, OHI, or POPGEN controls nor overlapped CNVs reported from non-BAC-based platforms in the Database of Genomic Variants (DGV) (Zhang et al. 2006 ) (http://projects.tcag.ca/variation, updated November 2010). Although we did not control for ancestry in this analysis, we did note which FPC-specific CNVs were detected in non-Caucasian samples.
Annotation of CNVs
Affymetrix 500K and Affymetrix 6.0 array coordinates were aligned to the NCBI hg17 and NCBI hg18 human genome builds, respectively. Genes overlapped by CNVs were identified through the UCSC genome browser (http:// genome.ucsc.edu/), using the respective human genome build. Information about CNV-overlapped genes was obtained from Entrez Gene (http://www.ncbi.nlm.nih.gov/ gene) and Pubmed (http://www.ncbi.nlm.nih.gov/pubmed/). The Memorial Sloan Kettering Cancer Centre (MSKCC) CancerGenes database (http://cbio.mskcc.org/CancerGenes/ Select.action) (Higgins et al. 2007 ) was used to identify genes with reported pathways or functions linked to cancer development. The Wellcome-Trust Sanger Catalogue of Somatic Mutations in Cancer (COSMIC-version 55) database (http://www.sanger.ac.uk/genetics/CGP/cosmic) (Shepherd et al. 2011) identified genes that had previously reported point mutations, small insertions/deletions, gene fusions, and copy number alterations in various tumors and cancer cell lines. The Pancreatic Expression Databaseversion 2.0 (http://www.pancreasexpression.org) (Cutts et al. 2011) identified genes which were reported to be differentially expressed or which were overlapped by copy number alterations in pancreatic tumors or pre-invasive lesions.
Comparing CNV profile between cases and controls Only ''high-confidence'' CNVs from non-EBV samples were included in the CNV profile comparison to minimize potential cell line artifacts and false calls (WTCCC et al. 2010) . As well, only controls with data available for both NspI and StyI chips were included in this comparison to minimize bias of undercalling CNVs in single-chip samples. To minimize CNV calling errors for ''complex'' CNVs (i.e. losses and gains in different samples overlapping the same region), we performed the ''rare CNV'' analysis only on regions reported as either losses or gains only. CNV loci that are present in fewer than 1 % of the total number of samples (cases ? controls) were considered ''rare'', excluding EBV samples and the complex CNVs. For losses, 32 cases and 235 controls (total 267 samples) were included in the ''rare loss'' analysis, so a rare loss was defined as present in fewer than three individuals. For gains, 56 cases and 551 controls (total 607 samples) were included in the ''rare gain'' analysis, so a rare gain was defined as present in fewer than seven samples.
Statistical analysis
Comparison of medians was performed using the MannWhitney U test and comparison of mean values was performed using the two-tailed Student's t test with Levene's test for equal variance. Testing for significant difference in proportions was performed with the two-tailed Fisher's exact test. A P value \0.05 was considered significant. Statistical testing was performed using the SPSSÓ software package (version 17).
Results
Affymetrix 500K results and validation STRUCTURE software was used for estimating population ancestry of the 120 FPC cases and 958 controls that had NspI ? StyI chips available for analysis: 89.2 % of cases and 94.8 % of controls were Caucasian, 1.7 % of cases and 2.1 % of controls were Asian, and 9.2 % of cases and 3.1 % of controls were of admixed background.
The total number of autosomal CNVs identified in cases and controls was 873 and 10,794, respectively, of which 382 CNVs (123 losses ? 259 gains) in cases and 3,115 CNVs (805 losses ? 2310 gains) in controls were considered high-confidence calls (corresponding to 66 loss loci ? 105 gain loci in cases and 313 loss loci ? 467 gain loci in controls). A combination of qPCR and Affymetrix 6.0 genotyping demonstrated a validation rate of 95 % (121/127) for high-confidence CNVs but only 45 % (66/ Table 1 compares several key CNV attributes between cases and controls (based on high-confidence CNVs and excluding EBV-derived samples and controls with only one chip in the analysis). Overall, no significant difference was observed in the CNV profile of cases and controls, including such parameters as CNV size, proportion of genic CNVs, proportion of rare CNVs, and average number of CNVs per individual genome. In both groups, gains were larger than losses (median size: cases 228.7 vs. 176.6 kb, P = 0.016; controls 224.4 vs. 168.0 kb, P \ 0.001) and were more likely to overlap genes (cases 153/190 gains vs. 52/91 losses are genic, P \ 0.001; controls 1,641/2,059 gains vs. 400/731 losses are genic, P \ 0.001).
Affymetrix 6.0 results
In 36 cases genotyped on the Affymetrix 6.0 array (two of the original 38 samples were excluded due to excess noise; see ''Methods''), a total of 3,364 autosomal CNVs (2,665 losses and 699 gains) were identified using Birdsuite, and 3,266 autosomal CNVs were identified using iPattern (1,975 losses ? 1,291 gains). The high-confidence set comprised 2,187 CNVs (1,656 losses ? 531 gains). The median size of high-confidence losses and gains was 12.7 kb (1 kb-1.4 Mb) and 48.9 kb (1 kb-1.6 Mb), respectively, and the average number of losses and gains per genome was 46 and 15, respectively.
FPC-specific CNVs
A total of 64 FPC CNVs (27 losses and 37 gains) detected on the 500K array were not identified in FGICR or OFCCR controls. After further excluding regions that overlapped POPGEN or OHI controls or were reported in the DGV, the number of FPC-specific CNVs identified on the 500K array is 37 CNVs (16 losses and 21 gains) . On the Affymetrix 6.0 array, 119 FPC CNVs (71 losses and 48 gains) were not identified in POPGEN or OHI controls, and after further excluding regions which overlapped FGICR and OFCCR controls or were in the DGV, 73 FPC-specific CNVs (45 losses and 28 gains) remained. Combining results from the two arrays (including regions identified on both platforms) yielded a total of 93 non-redundant FPC-specific CNVs (53 losses and 40 gains), each CNV present in a single individual only (a total of 50 FPC cases, including 7 EBVderived samples); 13 losses and 8 gains were in non-Caucasian individuals ( Fig. 1 and Table 2 ).
Twenty-three FPC-specific losses and 23 FPC-specific gains overlapped introns, exons, and/or untranslated regions of 104 RefSeq genes. Fourteen genes (including one small nuclear RNA) had at least part of their coding regions affected by FPC-specific losses, and 74 genes (including 3 microRNAs) had at least part of their coding . Fifty-five percent of those genes (48/88) have reported non-silent mutations (missense or nonsense variants, insertions/deletions, gene fusions) in different cancers according to the COSMIC v.55 database, whereas only 37 % of genes in all 500K ? Affymetrix 6.0 FPC CNVs (P = 0.002) and only 42 % of genes in all 500K ? Affymetrix 6.0 control CNVs (P = 0.022) had such mutations. None of the genes overlapped by FPC-specific losses were reported to have downregulated expression in pancreatic cancer in the Pancreatic Expression Database, whereas six genes overlapped by gains had reports of upregulation in pancreatic adenocarcinoma and three genes were reported to be upregulated in intraductal papillary mucinous neoplasm, a pre-invasive lesion. Furthermore, four FPC-specific gains overlapped regions reported to have high-level amplification in pancreatic adenocarcinoma in the Pancreatic Expression Database. The four gains overlap eight genes, of which three genes (LOC400643, DYNLRB2, LRRC30, and LAMA1) are entirely encompassed by their respective gains. LOC400643 is identified by NCBI Gene database as miscellaneous RNA with no information on its function. There are no reports of differential expression in pancreatic cancer or somatic mutations in DYNLRB2, which codes for a light chain component of cytoplasmic dynein 1 complex but this gene is reported to be involved in TGF-beta/ SMAD3 signaling (Jin et al. 2009 ) and reported to be downregulated in hepatocellular carcinoma (Jiang et al. 2001) . LRRC30, which codes for leucine-rich repeat-containing protein 30, has no reports of differential expression in pancreatic cancer or other association with tumorigenesis, but does have two reported mutations in the COSMIC database (one nonsense mutation in ovarian serous carcinoma and one missense mutation in hepatocellular carcinoma). LAMA1 codes for laminin, an extracellular matrix component that binds to cells via high-affinity receptors and mediates attachment, migration, and organization of cells into tissues during embryogenesis. The COSMIC v.55 database reports 18 protein-altering or truncating somatic mutations in this gene in tumors of the pancreas, ovary, central nervous system, large intestine, breast, upper aerodigestive tract, and skin. In comparison, for 10,849 COSMIC v.55 database genes that had at least one nonsilent/non-intronic mutation, the average number of mutations per gene is 3.7. A similar average number of reported somatic mutations is observed in genes affected by CNVs in our study (determined from the compiled data of 500K and Affymetrix 6.0 arrays): 3.6 mutations per gene for FPC-specific genes (P = 0.983), 3.4 mutations per gene for all FPC genes (P = 0.821), and 3.7 mutations per gene for all control genes (P = 0.955). There is also evidence for differential expression of LAMA1 in tumors of sites other than the pancreas; one study reported hypermethylation and under-expression of LAMA1 in colorectal cancer , while another study reported overexpression of this gene in glioblastoma (Scrideli et al. 2008) .
Discussion
Identifying predisposition genes associated with FPC has been challenging due to the rapid lethality of the disease, low rate of tumor resection (resulting in paucity of tissue specimens for analysis), and probable genetic heterogeneity. An estimated 20 % of hereditary cases are linked to cancer syndromes caused by alterations in known genes. However, most families that demonstrate clustering of pancreatic cancer do not meet criteria for known cancer syndromes (Klein et al. 2002) . We performed an analysis of germline CNVs in pancreatic cancer patients suspected to have a heritable genetic cause for their disease. These primarily included members of families with three or more affected cases, but also included families with only one or two affected cases if at least one of the cases was under age 50 at diagnosis. To date, this is the largest study of germline CNVs in unrelated cancer patients from high-risk families. A previous study of 57 pancreatic cancer patients from 56 highrisk kindreds (each containing at least a pair of affected first-degree relatives) used an oligonucleotide-based CGH platform to identify FPC-specific germline CNVs, filtering out losses or gains that were also identified in 607 controls (372 were analyzed in the same study, and 235 were previously reported in two other studies) (Lucito et al. 2007 ). Twenty-five FPC-specific losses overlapping 81 genes and 31 FPC-specific gains overlapping 425 genes were identified. In our study, we investigated 133 members of 131 high-risk kindreds, of whom 17 subjects were part of the previous CGH study, and we identified 93 FPC-specific CNVs using a combination of Affymetrix 500K and Affymetrix 6.0 arrays. The median size of FPC-specific CNVs in the CGH study was larger than in our FPC-specific CNVs (losses 151 vs. 35.5 kb, gains 379 vs. 73 kb). This may be due, in part, to the lower resolution of the CGH platform (mean inter-marker distance 30 kb) compared to the Affymetrix 500K array (median inter-marker distance 2.5 kb) and Affymetrix 6.0 array (median intermarker distance 0.7 kb) used in our study. It may also reflect enrichment for somatic CNVs caused by EBVtransformation, since all FPC DNA samples in the CGH study were extracted from EBV-transformed cells, whereas only 29 samples in our population were EBV lymphoblasts. The size of control populations used to filter CNVs was larger in our study and the number of control CNVs from non-BAC studies currently catalogued in the DGV is greater than was available at the time of publication of the previous FPC CNV study. As a result, some of the CNVs identified as ''FPC-specific'' in the previous study overlapped CNVs in our controls and/or in the DGV. This may explain the slightly higher (FPC-specific CNVs)-to-sample ratio observed in the CGH study (approximately 1 CNV per sample) compared to our study (0.8 CNV per sample).
It is difficult to estimate concordance in CNV calling between the two studies, as we do not know how many of the 56 FPC-specific CNVs reported in the CGH study were identified in samples that were also used in our study. Only 1/25 loss and 3/31 gain loci reported in the CGH study were also observed in our analysis in samples common to both studies, and all of these overlapped CNVs in our controls and/or in the DGV. Interestingly, multiple reports have demonstrated generally low concordance for CNV calling on different platforms/algorithms when analyzing the same DNA source (Pinto et al. 2011; Winchester et al. 2009 ). In addition to CNVs identified in cases common to both studies, there was one FPC-specific loss locus which was identified in two different subjects (one in each study). The region overlapped a gene, DOCK1 (dedicator of cytokinesis 1), but in our study the loss only encompassed an intronic portion of the gene. This gene may have a role in cellular proliferation and migration (Wang et al. 2010; Sanders et al. 2009 ), and it has been reported to be overexpressed in high-grade dysplastic lesions (PanIN3), suggesting that it may be important in advancing tumorigenesis (Buchholz et al. 2005) .
A number of other genome-wide germline CNV analyses have been reported for various cancers, but only a few have studied familial cancers. In addition to the aforementioned FPC study, microarray-based germline CNV studies have been reported for Li-Fraumeni syndrome (Shlien et al. 2008) , young-onset and/or familial colorectal cancer in families without mutations in known predisposition genes (Venkatachalam et al. 2011) , and BRCA1-associated ovarian cancer (Yoshihara et al. 2011 ). Shlien et al. described an increased frequency of germline CNVs in 33 Li-Fraumeni family members carrying mutations in the TP53 gene (of which 23 were affected by cancer), compared to 20 Li-Fraumeni family members with wildtype TP53 and 70 healthy controls. Since many of the CNVs overlapped or were near important cancer genes, the authors proposed a model whereby baseline genomic instability in these patients progresses over time, leading to more frequent and larger copy number alterations affecting genes that contribute to tumorigenesis. In our study, patients and controls had a similar number of alterations per genome, with similar CNV size, ratios of losses to gains, likelihood of CNVs to overlap genes, and proportion of genic CNVs that were associated with cancer. The lack of significant difference in the germline CNV profile between cases and controls suggests that causative genes for pancreatic cancer do not significantly impact genomic stability in non-tumor cells. Our results are similar to those of Yoshihara et al. who compared 68 Japanese subjects with germline BRCA1 mutations (of whom 51 had ovarian cancer), 34 sporadic ovarian cancer patients, and 47 healthy controls. They reported no significant difference in the per-genome total number of CNVs between BRCA1-mutation carriers and controls, although the number of deletions was higher in the BRCA1 subjects. Otherwise, they found no evidence for differential clustering of the global CNV data between groups, and no correlation of age at diagnosis with CNV frequency.
We identified 88 genes whose coding regions were partially or completely encompassed by FPC-specific CNVs, and although some are unlikely to be candidate FPC genes (e.g. olfactory receptor genes), many are functionally relevant to carcinogenesis, and are differentially expressed and/or overlap regions that are reported deleted or amplified in pancreatic adenocarcinoma (Online Resource 5). Moreover, the proportion of genes that were reported in COSMIC v.55 to have protein-altering mutations in tumors or malignant cell lines was significantly higher in FPCspecific genes than in either the full population of cases or in controls. This further suggests that FPC-specific CNVs are enriched for cancer-associated genes. In the report by Yoshihara et al., the primary genetic etiology for the hereditary cancer was already known (BRCA1), and the authors presented genes overlapped by BRCA1-specific CNVs as potential modifiers to the development of cancer. Alternatively, the study by Venkatachalam et al. identified seven genic CNVs specific to patients with familial colorectal cancer who have no known genetic mutation, each CNV found in a single individual only. In that study, like ours, each gene is considered a potential causative gene for familial colorectal cancer. None of the genes overlapped by cancer patient CNVs reported by Shlien et al., Yoshihara et al., or Venkatachalam et al. were part of our FPC-specific gene list.
In conclusion, we have presented a list of candidate predisposition genes for FPC overlapped by germline CNVs that are specific to the largest cohort of high-risk pancreatic cancer patients published to date. One limitation of our analysis is the coverage and resolution of the platform we used for primary CNV discovery (i.e. Affymetrix 500K array). Since the completion of our study, novel methods of CNV detection have become available, including very high resolution tiling microarrays and nextgeneration sequencing. We expect future studies using these methods to independently test our findings and detect additional FPC candidate genes. Some of the samples containing FPC-specific CNVs in our study differed in ancestry from the majority of controls, raising the possibility that these CNVs are specific to the respective ancestry group rather than to pancreatic cancer risk. Those CNVs should be investigated further in a larger ethnicitymatched control cohort. Despite these limitations, our list of FPC-specific genes contains several interesting candidates and further screening for mutations in other high-risk pancreatic cancer subjects, along with investigation of the functional role of these genes, would add support to the role of one or more genes in predisposition to FPC.
